Skip Navigation


Annals of Oncology Advance Access originally published online on February 23, 2006
Annals of Oncology 2006 17(9):1360-1369; doi:10.1093/annonc/mdl008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/9/1360    most recent
mdl008v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sawhney, R
Right arrow Articles by Chaudhary, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sawhney, R
Right arrow Articles by Chaudhary, U.
Related Collections
Right arrow 2006 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

reviews

Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead

R Sawhney1, D Bourgeois2 and UB Chaudhary1,*

1 Department of Medicine, Division of Hematology/Oncology, USA
2 Department of Pathology, Medical University of South Carolina, South Carolina, USA

*Correspondence to: Dr. U. B. Chaudhary, Medical University of South Carolina, Division of Hematology/Oncology, 96 Jonathan Lucas Street, 903 CSB, PO Box 250623, Charleston, SC 29425, USA. Tel: +1-843-792-4271; Fax: +1-843-792-0644; E-mail: chaudu{at}musc.edu

Randomized clinical trials of neo-adjuvant cisplatin-based combination chemotherapy for locally advanced muscle invasive bladder cancer has shown a survival benefit over cystectomy alone. Pathologic complete response (pT0) after neo-adjuvant chemotherapy is emerging as a potentially important surrogate clinical end point. Future clinical trials incorporating targeted therapies with novel clinical end points may accelerate development of therapeutic strategies for locally advanced muscle invasive bladder cancer. Furthermore, evaluation of molecular markers may further help to stratify patients to a risk adapted approach.

Key words: bladder cancer, chemotherapy, neoadjuvant, pT0


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.